Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > THTX failure

<< Previous

Bullboard Posts

Next >>

Comment by Biobobon Mar 18, 2022 1:15pm

138 Views

Post# 34525878

RE:RE:RE:RE:RE:RE:THTX failure

Ok shure, but now we are talking 50% down in a few months and going lower because even those large shareholders aren't buying anymore... insiders either. Like it occured in the past, forget analyst targets for now, what will the price of Th be in the next months.. 4$, 2$, 1$.. why not that would be 1 times sales and zero value for the pipeline.. it happened before and it will again if nothing happens like now.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing